"10.1371_journal.pone.0076740","plos one","2013-10-11T00:00:00Z","Shyny Koshy; Danli Wu; Xueyou Hu; Rajeev B Tajhya; Redwan Huq; Fatima S Khan; Michael W Pennington; Heike Wulff; Patricia Yotnda; Christine Beeton","Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas, United States of America; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, United States of America; Graduate Program in Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas, United States of America; Peptides International, Louisville, Kentucky, United States of America; Department of Pharmacology, University of California, Davis, California, United States of America","Conceived and designed the experiments: SK DW XH RBT RH PY CB. Performed the experiments: SK DW XH RBT RH FSK PY CB. Analyzed the data: SK DW XH RBT RH PY CB. Contributed reagents/materials/analysis tools: MWP HW. Wrote the paper: SK PY CB.","MWP and CB are inventors on a patent (WO2006042151A2) claiming ShK-186 and ShK- 192 for immunomodulation. This patent was licensed to Kineta Inc. for developing ShK-186 as a therapeutic for autoimmune diseases. MWP and CB are consultants to Kineta Inc. HW is inventor on a University of California patent (WO2006041800A3) claiming PAP-1 for immunosuppression. This patent was licensed to Airmid Inc. and subsequently sub-licensed to Circassia Inc. MWP, HW, and CB are co-founders of Airmid Inc. SK, DW, XH, RBT, RH, FSK, and PY declare no conflict of interest. The authors also confirm that this does not alter their adherence to the PLOS ONE policies on sharing data and materials.","2013","10","Shyny Koshy","SK",10,TRUE,7,8,7,3,TRUE,TRUE,FALSE,0,NA,FALSE
